Shuai Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shuai Zhang has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
Lei Song
Army Mil Med Univ, Mil Med Univ 3, Southwest Hosp, Orthoped Dept, 30 Gaotanyan St, Chongqing 400038, Peoples R China
4 shared publicationsJiaQi Zhao
Army Mil Med Univ, Mil Med Univ 3, Southwest Hosp, Orthoped Dept, 30 Gaotanyan St, Chongqing 400038, Peoples R China
3 shared publications- A. I. Qiuchi
Department of Orthopedics, the First Affiliated Hospital of Army Medical University, Chongqing, China
1 shared publication AiAi Li
Orthopedics Department, The First Affiliated Hospital of Army Medical University, Chongqing, China
1 shared publicationAlex Giorgiou
1 shared publication- Amish Lakhani
Radiology Department, Imperial College Healthcare NHS, Hammersmith Hospital, Du Cane Road, London W12 0HS, UK
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 13 January 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-10
Survival and prognostic factors among different types of liposarcomas based on SEER database
The aim of this study is to elucidate the disparities in survival and risk factors among different subtypes of liposarcoma, through analysis of epidemiological and prognostic data. The study cohort consisted of 12,822 patients diagnosed with liposarcoma in the United States between 2000 and 2021, whose data were retrieved from the Surveillance, Epidemiology, and End Results (SEER) program. The prognosis for different subtypes of liposarcoma and the associated factors such as age, tumor stage, intervention, gender, tumor grade, location, size, chemotherapy and radiotherapy, were retrieved from the database. Well-differentiated liposarcoma demonstrated the most favorable prognosis, with 5-year and 10-year survival rates of 82% and 68%, respectively, followed by myxoid liposarcoma, pleomorphic liposarcoma and dedifferentiated liposarcoma, which exhibited the poorest prognosis. Advanced age, higher tumor stage, and the absence of surgical intervention were associated with inferior survival outcomes across all subtypes. Male gender, higher pathological grade, and primary tumor sites outside the extremities were identified as risk factors for the prognosis of subtypes other than pleomorphic liposarcoma. Larger tumor size was an indicator of a worse prognosis in subtypes other than well-differentiated liposarcoma. Chemotherapy was a risk factor for the prognosis of well-differentiated and myxoid liposarcomas but had no significant correlation with the prognosis of pleomorphic and dedifferentiated liposarcomas. Radiotherapy served as a protective factor for the prognosis of subtypes other than well-differentiated liposarcoma. Survival and prognostic factors vary among the major subtypes of liposarcoma, necessitating individualized analysis for each subtype. Poorer outcomes can be anticipated in the dedifferentiated and pleomorphic subtypes, while well-differentiated and myxoid liposarcomas exhibit relatively favorable prognoses.
- 13 January 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-10
Top Cited PapersOpen AccessSurvival and prognostic factors among different types of liposarcomas based on SEER database
The aim of this study is to elucidate the disparities in survival and risk factors among different subtypes of liposarcoma, through analysis of epidemiological and prognostic data. The study cohort consisted of 12,822 patients diagnosed with liposarcoma in the United States between 2000 and 2021, whose data were retrieved from the Surveillance, Epidemiology, and End Results (SEER) program. The prognosis for different subtypes of liposarcoma and the associated factors such as age, tumor stage, intervention, gender, tumor grade, location, size, chemotherapy and radiotherapy, were retrieved from the database. Well-differentiated liposarcoma demonstrated the most favorable prognosis, with 5-year and 10-year survival rates of 82% and 68%, respectively, followed by myxoid liposarcoma, pleomorphic liposarcoma and dedifferentiated liposarcoma, which exhibited the poorest prognosis. Advanced age, higher tumor stage, and the absence of surgical intervention were associated with inferior survival outcomes across all subtypes. Male gender, higher pathological grade, and primary tumor sites outside the extremities were identified as risk factors for the prognosis of subtypes other than pleomorphic liposarcoma. Larger tumor size was an indicator of a worse prognosis in subtypes other than well-differentiated liposarcoma. Chemotherapy was a risk factor for the prognosis of well-differentiated and myxoid liposarcomas but had no significant correlation with the prognosis of pleomorphic and dedifferentiated liposarcomas. Radiotherapy served as a protective factor for the prognosis of subtypes other than well-differentiated liposarcoma. Survival and prognostic factors vary among the major subtypes of liposarcoma, necessitating individualized analysis for each subtype. Poorer outcomes can be anticipated in the dedifferentiated and pleomorphic subtypes, while well-differentiated and myxoid liposarcomas exhibit relatively favorable prognoses.
- Open Access
- 1 December 2024
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 16, 1823-1833
Clinical Outcome of Extended Curettage with Postoperative Denosumab Administration for the Treatment of Campanacci Grade III Giant Cell Tumors of the Extremities
Purpose: To investigate the local recurrence rate, joint preservation status, and functional outcomes after extended curettage and postoperative denosumab treatment for Campanacci Grade III giant cell tumors of the extremities. Methods: We retrospectively reviewed 23 patients with Campanacci Grade III GCTB of the extremities in our hospital between January 2017 and June 2023 who underwent extended curettage and postoperative denosumab administration alone, without preoperative denosumab treatment. Patients were followed-up for adverse events of denosumab, surgical outcomes, limb function of lesions, and local recurrence following extended curettage with postoperative denosumab. Results: All incisions healed without deep infections or internal fixation failure. The mean age of the patients at surgery was 36.6 years, and the mean follow-up was 35.8 months (range, 6-72 months). There of the 3 patients experienced a postoperative local recurrence. The recurrence rate was found to be 13.0%. Two patients were treated with repeat intralesional surgery with no additional recurrence two years later, and the other was treated with en bloc resection and reconstruction with a vascularized fibular graft. One patient experienced knee osteoarthritis without oral analgesics. No patient developed pulmonary metastases or malignant transformation of the GCTB. The mean Musculoskeletal Tumor Society functional score at the last follow up was 27.3 30 (range, 25-29). No serious adverse events were observed after the denosumab treatment. Conclusion: Our observations suggest that extended curettage with postoperative denosumab administration is a reasonable option for treating Campanacci Grade III giant cell tumors of the extremities. Extended curettage with adjuvant denosumab therapy results in beneficial surgical downstaging, including a less morbid surgical procedure or delayed en bloc resection. Resection should be considered when the structural integrity cannot be regained after bone grafting or bone cement filling combined with internal fixation.
- 1 December 2024
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 16, 1823-1833
Open AccessClinical Outcome of Extended Curettage with Postoperative Denosumab Administration for the Treatment of Campanacci Grade III Giant Cell Tumors of the Extremities
Purpose: To investigate the local recurrence rate, joint preservation status, and functional outcomes after extended curettage and postoperative denosumab treatment for Campanacci Grade III giant cell tumors of the extremities. Methods: We retrospectively reviewed 23 patients with Campanacci Grade III GCTB of the extremities in our hospital between January 2017 and June 2023 who underwent extended curettage and postoperative denosumab administration alone, without preoperative denosumab treatment. Patients were followed-up for adverse events of denosumab, surgical outcomes, limb function of lesions, and local recurrence following extended curettage with postoperative denosumab. Results: All incisions healed without deep infections or internal fixation failure. The mean age of the patients at surgery was 36.6 years, and the mean follow-up was 35.8 months (range, 6-72 months). There of the 3 patients experienced a postoperative local recurrence. The recurrence rate was found to be 13.0%. Two patients were treated with repeat intralesional surgery with no additional recurrence two years later, and the other was treated with en bloc resection and reconstruction with a vascularized fibular graft. One patient experienced knee osteoarthritis without oral analgesics. No patient developed pulmonary metastases or malignant transformation of the GCTB. The mean Musculoskeletal Tumor Society functional score at the last follow up was 27.3 30 (range, 25-29). No serious adverse events were observed after the denosumab treatment. Conclusion: Our observations suggest that extended curettage with postoperative denosumab administration is a reasonable option for treating Campanacci Grade III giant cell tumors of the extremities. Extended curettage with adjuvant denosumab therapy results in beneficial surgical downstaging, including a less morbid surgical procedure or delayed en bloc resection. Resection should be considered when the structural integrity cannot be regained after bone grafting or bone cement filling combined with internal fixation.
- Open Access
- 3 January 2024
- Published by Springer Nature in Research Square
Differential analysis of inflammatory markers in benign and malignant bone tumor patients based on a large cohort of cases
Objective To explore the relationship between inflammatory markers and the benign-malignant nature as well as tumor staging of primary bone tumors using a comprehensive analysis of a substantial cohort of cases. Methods Clinical data of patients with primary bone tumors in the limbs were collected. Subsequently, patients were classified into two distinct groups: benign bone tumors group and primary malignant bone tumors group. Various inflammatory markers including neutrophil count, lymphocyte count, and platelet count were recorded from preoperative complete blood cell counts. Additionally, the neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) were calculated. The potential differences in these aforementioned inflammatory markers between the two groups were compared and analyzed. Furthermore, based on the Enneking tumor staging, patients from the two group were reassigned into subgroups, respectively, and these inflammatory markers among patients at different tumor stages were compared and analyzed. Results A total of 315 patients with benign bone tumors and 256 patients with primary malignant bone tumors were included in this study. In terms of inflammatory markers, the mean neutrophil count, the mean platelet count, the mean NLR value and the mean PLR value were 3.45 ± 1.13, 213.56 ± 58.19, 1.92 ± 0.79 and 118.86 ± 42.43 in the benign bone tumor group and 4.14 ± 1.65, 235.32 ± 74.45, 2.48 ± 1.74 and 136.77 ± 67.91 in the malignant bone tumor group (P < 0.05). In the benign group, there were 110 patients in Enneking stage 1 and 33 patients in stage 3. The mean neutrophil count and the mean lymphocyte count were 3.12 ± 0.97, 1.85 ± 0.54 in stage 1 and 3.86 ± 1.25, 2.11 ± 0.63 in stage 3 (P < 0.05). While in the malignant group, there were 38 patients in Enneking stage I and 31 patients in stage III. The mean neutrophil count, the mean NLR value and the mean PLR were 3.61 ± 1.06, 1.93 ± 0.82, 118.80 ± 43.39 in stage I and 4.77 ± 2.18, 3.17 ± 2.76, 149.15 ± 70.24 in stage III (P < 0.05). Conclusion This study provides clinical evidence supporting the close relationship between inflammation and the pathogenesis of primary bone tumors. It reveals that patients with primary malignant bone tumors exhibit significantly elevated levels of inflammatory markers, compared to those with benign bone tumors.
- 3 January 2024
- Published by Springer Nature in Research Square
Open AccessDifferential analysis of inflammatory markers in benign and malignant bone tumor patients based on a large cohort of cases
Objective To explore the relationship between inflammatory markers and the benign-malignant nature as well as tumor staging of primary bone tumors using a comprehensive analysis of a substantial cohort of cases. Methods Clinical data of patients with primary bone tumors in the limbs were collected. Subsequently, patients were classified into two distinct groups: benign bone tumors group and primary malignant bone tumors group. Various inflammatory markers including neutrophil count, lymphocyte count, and platelet count were recorded from preoperative complete blood cell counts. Additionally, the neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) were calculated. The potential differences in these aforementioned inflammatory markers between the two groups were compared and analyzed. Furthermore, based on the Enneking tumor staging, patients from the two group were reassigned into subgroups, respectively, and these inflammatory markers among patients at different tumor stages were compared and analyzed. Results A total of 315 patients with benign bone tumors and 256 patients with primary malignant bone tumors were included in this study. In terms of inflammatory markers, the mean neutrophil count, the mean platelet count, the mean NLR value and the mean PLR value were 3.45 ± 1.13, 213.56 ± 58.19, 1.92 ± 0.79 and 118.86 ± 42.43 in the benign bone tumor group and 4.14 ± 1.65, 235.32 ± 74.45, 2.48 ± 1.74 and 136.77 ± 67.91 in the malignant bone tumor group (P < 0.05). In the benign group, there were 110 patients in Enneking stage 1 and 33 patients in stage 3. The mean neutrophil count and the mean lymphocyte count were 3.12 ± 0.97, 1.85 ± 0.54 in stage 1 and 3.86 ± 1.25, 2.11 ± 0.63 in stage 3 (P < 0.05). While in the malignant group, there were 38 patients in Enneking stage I and 31 patients in stage III. The mean neutrophil count, the mean NLR value and the mean PLR were 3.61 ± 1.06, 1.93 ± 0.82, 118.80 ± 43.39 in stage I and 4.77 ± 2.18, 3.17 ± 2.76, 149.15 ± 70.24 in stage III (P < 0.05). Conclusion This study provides clinical evidence supporting the close relationship between inflammation and the pathogenesis of primary bone tumors. It reveals that patients with primary malignant bone tumors exhibit significantly elevated levels of inflammatory markers, compared to those with benign bone tumors.
- Open Access
- 20 December 2023
- Published by Springer Nature in Research Square
Clinical outcome of extended curettage with postoperative denosumab administration for the treatment of Campanacci Grade III giant cell tumors of the extremities
Background Management of Campanacci Grade III giant cell tumors of the extremities is controversial because wide resection with reconstruction results in a poor functional outcome for most patients. Denosumab has been used before operation to enable curettage and surgical downstaging in patients with giant cell tumor of bone (GCTB), where joint preservation is difficult. However, owing to osteosclerosis of the lesion and difficulty to curet the lesion thoroughly, preoperative denosumab treatment increases the local recurrence rate. It is unclear whether postoperative treatment with denosumab facilitate the ability of a joint to be salvaged by intralesional surgery instead of resection. Therefore, we performed a retrospective study to investigate the local recurrence rate, joint preservation status, and functional outcomes after extended curettage and postoperative denosumab treatment in Campanacci Grade III giant cell tumors of the extremities. Methods We retrospectively reviewed 23 patients with Campanacci Grade III GCTB of the extremities in our hospital from January 2017 to June 2023, who underwent extended curettage and postoperative denosumab administration alone, without preoperative denosumab treatment. Patients were followed for adverse events of denosumab, surgical outcome, limb function of lesions, and local recurrence following extended curettage with postoperative denosumab . Results All incisions were healed without deep infection and internal fixation failure. The mean age of the patients at surgery was 36.6 years, and the mean followup was 35.8 months ( range, 6–72 months). There of the 23 patients had local recurrence years postoperatively. The recurrence rate is 13.0%. Two was treated with repeat intralesional surgery with no additional recurrence 2 years later, and another was treated with en bloc resection and reconstruction with vascularised fibular graft. One patient had progression to knee osteoarthritis without oral analgesics. No patient had pulmonary metastases develop and malignant transformation of GCTB. The mean Musculoskeletal Tumor Society functional scores at last followup were 27.3 of 30 (range,25–29). No serious adverse events were detected due to denosumab. Conclusion Our observations suggest extended curettage with postoperative denosumab administration is a reasonable option for Campanacci Grade III giant cell tumors of the extremities. Extended curettage with adjuvant denosumab therapy resulted in beneficial surgical downstaging, including either a less morbid surgical procedure or delayed en bloc resection. Maybe, resection should be considered when structural integrity cannot be regained after bone grafting or bone cement filling combined with intemal fixation.
- 20 December 2023
- Published by Springer Nature in Research Square
Open AccessClinical outcome of extended curettage with postoperative denosumab administration for the treatment of Campanacci Grade III giant cell tumors of the extremities
Background Management of Campanacci Grade III giant cell tumors of the extremities is controversial because wide resection with reconstruction results in a poor functional outcome for most patients. Denosumab has been used before operation to enable curettage and surgical downstaging in patients with giant cell tumor of bone (GCTB), where joint preservation is difficult. However, owing to osteosclerosis of the lesion and difficulty to curet the lesion thoroughly, preoperative denosumab treatment increases the local recurrence rate. It is unclear whether postoperative treatment with denosumab facilitate the ability of a joint to be salvaged by intralesional surgery instead of resection. Therefore, we performed a retrospective study to investigate the local recurrence rate, joint preservation status, and functional outcomes after extended curettage and postoperative denosumab treatment in Campanacci Grade III giant cell tumors of the extremities. Methods We retrospectively reviewed 23 patients with Campanacci Grade III GCTB of the extremities in our hospital from January 2017 to June 2023, who underwent extended curettage and postoperative denosumab administration alone, without preoperative denosumab treatment. Patients were followed for adverse events of denosumab, surgical outcome, limb function of lesions, and local recurrence following extended curettage with postoperative denosumab . Results All incisions were healed without deep infection and internal fixation failure. The mean age of the patients at surgery was 36.6 years, and the mean followup was 35.8 months ( range, 6–72 months). There of the 23 patients had local recurrence years postoperatively. The recurrence rate is 13.0%. Two was treated with repeat intralesional surgery with no additional recurrence 2 years later, and another was treated with en bloc resection and reconstruction with vascularised fibular graft. One patient had progression to knee osteoarthritis without oral analgesics. No patient had pulmonary metastases develop and malignant transformation of GCTB. The mean Musculoskeletal Tumor Society functional scores at last followup were 27.3 of 30 (range,25–29). No serious adverse events were detected due to denosumab. Conclusion Our observations suggest extended curettage with postoperative denosumab administration is a reasonable option for Campanacci Grade III giant cell tumors of the extremities. Extended curettage with adjuvant denosumab therapy resulted in beneficial surgical downstaging, including either a less morbid surgical procedure or delayed en bloc resection. Maybe, resection should be considered when structural integrity cannot be regained after bone grafting or bone cement filling combined with intemal fixation.
- 10 February 2022
- Published by Elsevier in Lung Cancer
- Vol. 165, S32
Clinical predictors of long-term efficacy of first-line pembrolizumab monotherapy in non-small cell lung cancer (NSCLC): an interim analysis of real-world data
- 10 February 2022
- Published by Elsevier in Lung Cancer
- Vol. 165, S32
Clinical predictors of long-term efficacy of first-line pembrolizumab monotherapy in non-small cell lung cancer (NSCLC): an interim analysis of real-world data
- Open Access
- 13 July 2021
- Published by Springer Nature in Research Square
Retrospective Review of Safety and Efficacy of Anlotinib in Advanced Osteosarcoma With Metastases After Failure of Standard Multimodal Therapy
To study and observe the safety and efficacy of anlotinib in the treatment of advanced osteosarcoma with metastases. We retrospectively studied patients with advanced osteosarcoma and metastases who received anlotinib treatment in our hospital from June 2018 to April 2020. All patients had received standard multimodal therapies, before taking anlotinib. Therapeutic doses of anlotinib were 12 mg for adults and 10 mg for children and adolescents once a day for 2 consecutive weeks, followed by a week of withdrawal. This 3-week cycle of treatment was continued until the tumor progressed rapidly or the patients failed to tolerate the side effects. Adverse drug reactions were recorded, and therapeutic efficacy was evaluated based on progression free survival (PFS), disease control rate (DCR), overall survival (OS), and objective response rate (ORR). The median PFS was 9.81 ± 0.9 months, and the 6-month and 10-month PFS rates were 73.3% and 33.3%, respectively. The median OS was 11.43 ± 0.58 months. No patients achieved complete response. After 6 months of treatment, the DCR and ORR were 80% and 13.3%, respectively. No drug-related deaths or Grade 4 adverse events occurred in the patients. Five patients (33.3%) had Grade 3 adverse events. The most common drug-related adverse events were hand-food syndrome, fatigue, high blood pressure, anorexia, and pneumothorax. Anlotinib had a certain curative effect on patients with advanced osteosarcoma and metastases after failure of standard treatment. The adverse events were mostly tolerable or relieved after treatment.
- 13 July 2021
- Published by Springer Nature in Research Square
Open AccessRetrospective Review of Safety and Efficacy of Anlotinib in Advanced Osteosarcoma With Metastases After Failure of Standard Multimodal Therapy
To study and observe the safety and efficacy of anlotinib in the treatment of advanced osteosarcoma with metastases. We retrospectively studied patients with advanced osteosarcoma and metastases who received anlotinib treatment in our hospital from June 2018 to April 2020. All patients had received standard multimodal therapies, before taking anlotinib. Therapeutic doses of anlotinib were 12 mg for adults and 10 mg for children and adolescents once a day for 2 consecutive weeks, followed by a week of withdrawal. This 3-week cycle of treatment was continued until the tumor progressed rapidly or the patients failed to tolerate the side effects. Adverse drug reactions were recorded, and therapeutic efficacy was evaluated based on progression free survival (PFS), disease control rate (DCR), overall survival (OS), and objective response rate (ORR). The median PFS was 9.81 ± 0.9 months, and the 6-month and 10-month PFS rates were 73.3% and 33.3%, respectively. The median OS was 11.43 ± 0.58 months. No patients achieved complete response. After 6 months of treatment, the DCR and ORR were 80% and 13.3%, respectively. No drug-related deaths or Grade 4 adverse events occurred in the patients. Five patients (33.3%) had Grade 3 adverse events. The most common drug-related adverse events were hand-food syndrome, fatigue, high blood pressure, anorexia, and pneumothorax. Anlotinib had a certain curative effect on patients with advanced osteosarcoma and metastases after failure of standard treatment. The adverse events were mostly tolerable or relieved after treatment.
- Open Access
- 26 May 2021
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 19 (1) , 1-10
Comparative efficacy of intraoperative extracorporeal irradiated and alcohol-inactivated autograft reimplantation for the management of osteosarcomas—a multicentre retrospective study
Biologic bone reconstruction in limb salvage surgery for the treatment of malignant bone tumours has always been controversial. The various inactivation methods, their convenience and stability, the curative effects elicited and associated costs all need to be considered. This study aimed to compare the clinical efficacy of intraoperative extracorporeal irradiated reimplantation with alcohol-inactivated autograft reimplantation for limb salvage surgery in patients with osteosarcoma. We retrospectively analysed 28 patients with osteosarcoma, 14 patients treated with intraoperative cobalt 60 irradiation and reimplantation (group A), and 14 patients treated by alcohol-inactivated autograft reimplantation (group B). The postoperative complications and clinical efficacy of each treatment method were compared by statistical analysis. The local recurrence rate was 14.3% in each group. Complete bony union was achieved in 64.3% of patients in group A and 71.4% of patients in group B. The overall 5-year survival rate was 71.4% in group A and 78.6% in group B. The mean Musculoskeletal Tumor Society (MSTS) score was 25.33 ± 4.72 (range 15–30) in group A and 24.00 ± 5.85 (range 15–30) in group B, and the mean International Society of Limb Salvage (ISOLS) score was 25.79 ± 5.13 (range 20–36) in group A and 26.14 ± 5.33 (range 20–30) in group B. P < 0.05 was considered to indicate a significant difference. The results showed that the long-term clinical efficacy did not differ significantly between the two methods. In limb salvage surgery for osteosarcoma, intraoperative extracorporeal irradiation and alcohol-inactivated autograft reimplantation yielded equivalent outcomes. The alcohol-inactivated method may be a much more convenient and inexpensive way to reconstruct bone defects. Additional studies as well as more case studies are needed to fully evaluate the clinical efficacy and safety of this treatment method.
- 26 May 2021
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 19 (1) , 1-10
Open AccessComparative efficacy of intraoperative extracorporeal irradiated and alcohol-inactivated autograft reimplantation for the management of osteosarcomas—a multicentre retrospective study
Biologic bone reconstruction in limb salvage surgery for the treatment of malignant bone tumours has always been controversial. The various inactivation methods, their convenience and stability, the curative effects elicited and associated costs all need to be considered. This study aimed to compare the clinical efficacy of intraoperative extracorporeal irradiated reimplantation with alcohol-inactivated autograft reimplantation for limb salvage surgery in patients with osteosarcoma. We retrospectively analysed 28 patients with osteosarcoma, 14 patients treated with intraoperative cobalt 60 irradiation and reimplantation (group A), and 14 patients treated by alcohol-inactivated autograft reimplantation (group B). The postoperative complications and clinical efficacy of each treatment method were compared by statistical analysis. The local recurrence rate was 14.3% in each group. Complete bony union was achieved in 64.3% of patients in group A and 71.4% of patients in group B. The overall 5-year survival rate was 71.4% in group A and 78.6% in group B. The mean Musculoskeletal Tumor Society (MSTS) score was 25.33 ± 4.72 (range 15–30) in group A and 24.00 ± 5.85 (range 15–30) in group B, and the mean International Society of Limb Salvage (ISOLS) score was 25.79 ± 5.13 (range 20–36) in group A and 26.14 ± 5.33 (range 20–30) in group B. P < 0.05 was considered to indicate a significant difference. The results showed that the long-term clinical efficacy did not differ significantly between the two methods. In limb salvage surgery for osteosarcoma, intraoperative extracorporeal irradiation and alcohol-inactivated autograft reimplantation yielded equivalent outcomes. The alcohol-inactivated method may be a much more convenient and inexpensive way to reconstruct bone defects. Additional studies as well as more case studies are needed to fully evaluate the clinical efficacy and safety of this treatment method.
- Open Access
- 16 May 2014
- Published by Spandidos Publications in Oncology Letters
- Vol. 8 (2) , 663-666
Primary dedifferentiated liposarcoma of the femur presenting with malignant fibrous histiocytoma: A case report and review of the literature
In the current report a case of a 26-year-old male with a primary dedifferentiated liposarcoma of the femur accompanied by malignant fibrous histiocytoma is presented. The patient complained of a dull intermittent pain, for three months, along the anterolateral aspect of the right knee and was referred to Southwest Hospital (Chongqing, China) in May 2013. All of the radiographic findings, including radiography, magnetic resonance image and emission computed tomography (CT) supported the diagnosis of a primary malignant bone tumor. CT-guided biopsy results demonstrated blood clots and a small quantity of heterogeneous cells. Thus, a limb‑salvage procedure, involving a wide resection and total knee endoprosthesis replacement, was performed in May 2012. The final pathological diagnosis was of a primary dedifferentiated liposarcoma of the femur and the dedifferentiated tissue was identified as malignant fibrous histiocytoma. On review of the literature, it was identified that primary intraosseous liposarcoma are a rare and malignant tumor of the skeletal system, with only a small number of cases reported in the English literature since 1980. To the best of our knowledge, a case of dedifferentiated liposarcoma has not previously been reported.
- 16 May 2014
- Published by Spandidos Publications in Oncology Letters
- Vol. 8 (2) , 663-666
Open AccessPrimary dedifferentiated liposarcoma of the femur presenting with malignant fibrous histiocytoma: A case report and review of the literature
In the current report a case of a 26-year-old male with a primary dedifferentiated liposarcoma of the femur accompanied by malignant fibrous histiocytoma is presented. The patient complained of a dull intermittent pain, for three months, along the anterolateral aspect of the right knee and was referred to Southwest Hospital (Chongqing, China) in May 2013. All of the radiographic findings, including radiography, magnetic resonance image and emission computed tomography (CT) supported the diagnosis of a primary malignant bone tumor. CT-guided biopsy results demonstrated blood clots and a small quantity of heterogeneous cells. Thus, a limb‑salvage procedure, involving a wide resection and total knee endoprosthesis replacement, was performed in May 2012. The final pathological diagnosis was of a primary dedifferentiated liposarcoma of the femur and the dedifferentiated tissue was identified as malignant fibrous histiocytoma. On review of the literature, it was identified that primary intraosseous liposarcoma are a rare and malignant tumor of the skeletal system, with only a small number of cases reported in the English literature since 1980. To the best of our knowledge, a case of dedifferentiated liposarcoma has not previously been reported.